Who owns Insight Molecular Diagnostics Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings.
Institutional ownership of IMDX from SEC Form 13F filings across 31 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 31 institutions disclosed 15.5M shares of Insight Molecular Diagnostics Inc. worth $90.2M — about 42.1% of shares outstanding; the largest disclosed holder is BROADWOOD CAPITAL INC. Source: SEC Form 13F filings, parsed by EvidInvest.
31
13F holders
$90.2M
value, 2026 filers
42.1%
of shares outstanding (15.5M sh)
11
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30· % of fund = share of the manager's own book · % of co. = share of IMDX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BROADWOOD CAPITAL INC | 12.7M | $74.8M | 3.9% | 34.5% | +6.3% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 735,847 | $4.3M | 0.0% | 2% | -31.5% |
| 3 | PURA VIDA INVESTMENTS, LLC | 484,845 | $2.9M | 17.3% | 1.3% | -48.8% |
| 4 | Family Office Research LLC | 368,849 | $2.2M | 0.8% | 1% | +189.8% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 256,903 | $1.5M | 0.0% | 0.7% | -2.0% |
| 6 | FNY Investment Advisers, LLC | 182,561 | $1,077 | 0.4% | 0.5% | -26.2% |
| 7 | JANE STREET GROUP, LLCNEW | 157,682 | $930,324 | 0.0% | 0.4% | new |
| 8 | BlackRock, Inc. | 150,521 | $888,074 | 0.0% | 0.4% | +11.2% |
| 9 | VANGUARD FIDUCIARY TRUST CO | 124,576 | $734,998 | 0.0% | 0.3% | -6.0% |
| 10 | MILLENNIUM MANAGEMENT LLC | 82,499 | $486,744 | 0.0% | 0.2% | -20.3% |
| 11 | UBS Group AG | 53,276 | $314,329 | 0.0% | 0.1% | +134.2% |
| 12 | NORTHERN TRUST CORP | 49,090 | $289,631 | 0.0% | 0.1% | 0.0% |
| 13 | OSAIC HOLDINGS, INC. | 39,136 | $230,901 | 0.0% | 0.1% | +62.2% |
| 14 | MORGAN STANLEY | 35,515 | $209,539 | 0.0% | 0.1% | -1.6% |
| 15 | MARSHALL WACE, LLPNEW | 16,597 | $97,922 | 0.0% | 0% | new |
| 16 | ExodusPoint Capital Management, LPNEW | 14,029 | $82,771 | 0.0% | 0% | new |
| 17 | TWO SIGMA INVESTMENTS, LPNEW | 11,101 | $65,496 | 0.0% | 0% | new |
| 18 | BNP PARIBAS FINANCIAL MARKETS | 5,801 | $34,226 | 0.0% | 0% | +8964.1% |
| 19 | Vanguard Global Advisers, LLC | 5,775 | $34,073 | 0.0% | 0% | 0.0% |
| 20 | EverSource Wealth Advisors, LLC | 5,000 | $29,500 | 0.0% | 0% | -0.5% |
| 21 | Tower Research Capital LLC (TRC)NEW | 2,691 | $15,877 | 0.0% | 0% | new |
| 22 | Steward Partners Investment Advisory, LLCNEW | 1,960 | $11,564 | 0.0% | 0% | new |
| 23 | ROYAL BANK OF CANADANEW | 251 | $1,000 | 0.0% | 0% | new |
| 24 | SBI Securities Co., Ltd. | 185 | $1,092 | 0.0% | 0% | 0.0% |
| 25 | JPMORGAN CHASE & CO | 154 | $835 | 0.0% | 0% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.